Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAURENCE H BELKOFF

Allopathic & Osteopathic Physicians Urology

NPI
1689679938
CMS profile
258352
Location
BALA CYNWYD, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$6,894.67

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,230.17 104
Consulting Fee $3,220.00 1
Travel and Lodging $359.50 2
Education $85.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAURENCE H BELKOFF

NPI 1689679938 · CMS profile ID 258352

Allopathic & Osteopathic Physicians / Urology

BALA CYNWYD, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689679938?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAURENCE H BELKOFF, NPI 1689679938, CMS profile ID 258352. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689679938?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). LAURENCE H BELKOFF, NPI 1689679938, CMS profile ID 258352. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689679938?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
LAURENCE H BELKOFF, NPI 1689679938, CMS profile ID 258352, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1689679938?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $6,894.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–108 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $20.9902/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940118133 CMS
ABBVIE INC. $11.4602/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890587965 CMS
PFIZER INC. $14.2302/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949131927 CMS
UROVANT SCIENCES INC $17.3501/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 931054127 CMS
Sun Pharmaceutical Industries Inc. $23.7801/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947823599 CMS
UroGen Pharma, Inc. $23.8001/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907970929 CMS
Myovant Sciences Inc. $15.8301/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941179763 CMS
Astellas Pharma US Inc $85.0001/05/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940096015 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,330.19 78
PY2020 $3,773.65 44
PY2021 $3,450.95 98
PY2022 $6,894.67 108
PY2023 $2,736.26 81
PY2024 $9,140.12 108
PY2025 $15,095.21 118

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,626.00 1
PY2025 Principal investigator $2,361,417.34 207
PY2024 Principal investigator $3,029,808.39 208
PY2023 Principal investigator $2,730,616.25 244
PY2022 Principal investigator $4,084,891.54 189
PY2021 Principal investigator $2,950,941.30 132
PY2020 Principal investigator $2,563,048.00 292
PY2019 Principal investigator $895,863.11 222

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

208 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $10,129.43 12/31/2025 Non-covered Recipient Entity
MidLantic urology
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett No dispute reported 06/30/2026 1232925151
Principal investigator 1 Merck Sharp & Dohme LLC $49,555.33 12/31/2025 Non-covered Recipient Entity
MidLantic urology
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926787
Principal investigator 1 Merck Sharp & Dohme LLC $180,022.93 12/31/2025 Non-covered Recipient Entity
MidLantic urology
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926789
Principal investigator 1 Merck Sharp & Dohme LLC $12,322.38 12/31/2025 Non-covered Recipient Entity
MidLantic urology
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 No dispute reported 06/30/2026 1232927525
Principal investigator 1 Merck Sharp & Dohme LLC $38,620.21 12/31/2025 Non-covered Recipient Entity
MidLantic urology
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-B15 , EV-304 No dispute reported 06/30/2026 1232927539
Principal investigator 1 Merck Sharp & Dohme LLC $16,731.35 12/31/2025 Non-covered Recipient Entity
MidLantic urology
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer No dispute reported 06/30/2026 1232928025
Principal investigator 1 Merck Sharp & Dohme LLC $20,482.77 12/31/2025 Non-covered Recipient Entity
MidLantic urology
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor No dispute reported 06/30/2026 1232930203
Principal investigator 1 Merck Sharp & Dohme LLC $11,014.20 12/31/2025 Non-covered Recipient Entity
MidLantic urology
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232935105
Principal investigator 1 Merck Sharp & Dohme LLC $193,571.57 12/29/2025 Non-covered Recipient Entity
MidLantic urology
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926785
Principal investigator 1 Janssen Research & Development, LLC $8,066.00 12/26/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175378838
Principal investigator 1 Janssen Research & Development, LLC $7,766.00 12/25/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175378759
Principal investigator 1 MEDIVATION LLC. $240.50 12/24/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740725
Principal investigator 1 Janssen Research & Development, LLC $115.00 12/22/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264399
Principal investigator 1 Janssen Research & Development, LLC $8,700.00 12/22/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264444
Principal investigator 1 Janssen Research & Development, LLC $88.00 12/22/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264512
Principal investigator 1 Janssen Research & Development, LLC $5,950.00 12/22/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175379103
Principal investigator 1 Sumitomo Pharma America, Inc. $3,156.00 12/22/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLP DBA MIDLANTIC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657727
Principal investigator 1 Sumitomo Pharma America, Inc. $5,620.00 12/22/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLP DBA MIDLANTIC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657735
Principal investigator 1 Janssen Research & Development, LLC $898.00 12/18/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175378861
Principal investigator 1 Janssen Research & Development, LLC $27,462.00 12/18/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175379139
Principal investigator 1 Janssen Research & Development, LLC $17,222.00 12/15/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175378900
Principal investigator 1 AstraZeneca UK Limited $12,980.00 12/05/2025 Non-covered Recipient Entity
MIDLANTIC UROLOGY LLC
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185543192
Principal investigator 1 Merck Sharp & Dohme LLC $65,170.00 12/03/2025 Non-covered Recipient Entity
MidLantic urology
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232935103
Principal investigator 1 Janssen Research & Development, LLC $3,860.00 12/01/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175379065
Principal investigator 1 Janssen Research & Development, LLC $4,338.00 11/28/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175378938
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $120.18 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409566
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409576
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $77.50 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409580
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,980.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409582
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409620
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $210.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409622
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $96.81 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409630
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409642
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $210.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409654
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $96.81 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409670
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $77.50 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409680
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $163.58 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409690
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409700
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $51.19 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409702
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $51.19 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409708
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $120.18 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409720
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409724
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409752
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $163.58 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409762
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $99.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409764
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $51.19 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409776
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $210.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409788
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $120.18 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409790
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409796
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $163.58 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409814
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $210.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409816
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $77.50 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409820
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $99.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409830
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $96.81 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409836
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $715.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409840
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $715.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409842
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,018.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409856
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $99.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409874
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409890
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 11/27/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409906
Principal investigator 1 Janssen Research & Development, LLC $2,165.00 11/27/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175378947
Principal investigator 1 Janssen Research & Development, LLC $2,173.00 11/24/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264383
Principal investigator 1 Janssen Research & Development, LLC $7,466.00 11/24/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175378793
Principal investigator 1 Janssen Research & Development, LLC $2,116.40 11/24/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175379018
Principal investigator 1 Janssen Research & Development, LLC $107.00 11/21/2025 Non-covered Recipient Entity
Urologic Consultants Of Southeastern Pennsylvania Admn
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175264427
Principal investigator 1 Janssen Research & Development, LLC $2,897.00 11/21/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175379082
Principal investigator 1 Janssen Research & Development, LLC $3,632.00 11/18/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175378909
Principal investigator 1 Merck Sharp & Dohme LLC $14,686.00 11/17/2025 Non-covered Recipient Entity
MidLantic urology
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 No dispute reported 06/30/2026 1232927355
Principal investigator 1 Janssen Research & Development, LLC $1,918.00 11/14/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264486
Principal investigator 1 Janssen Research & Development, LLC $16,132.00 11/07/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175379177
Principal investigator 1 Janssen Research & Development, LLC $1,384.00 11/03/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175379187
Principal investigator 1 Janssen Research & Development, LLC $15,765.00 11/03/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175379195
Principal investigator 1 Janssen Research & Development, LLC $450.05 10/27/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175378876
Principal investigator 1 Janssen Research & Development, LLC $47,000.00 10/17/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175378882
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,334.82 10/15/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410286
Principal investigator 1 Janssen Research & Development, LLC $2,440.00 10/13/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175378830
Principal investigator 1 Janssen Research & Development, LLC $158.00 10/07/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264365
Principal investigator 1 Janssen Research & Development, LLC $1,704.00 10/07/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264374
Principal investigator 1 Janssen Research & Development, LLC $3,327.00 10/07/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264436
Principal investigator 1 Janssen Research & Development, LLC $2,982.00 10/07/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264466
Principal investigator 1 Janssen Research & Development, LLC $426.00 10/07/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264493
Principal investigator 1 Janssen Research & Development, LLC $2,370.00 10/07/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264549
Principal investigator 1 Janssen Research & Development, LLC $8,066.00 10/06/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175378846
Principal investigator 1 Janssen Research & Development, LLC $4,270.00 10/06/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175379050
Principal investigator 1 Janssen Research & Development, LLC $3,096.00 10/02/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175264504
Principal investigator 1 Janssen Research & Development, LLC $4,171.00 10/02/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175379147
Principal investigator 1 Janssen Research & Development, LLC $6,123.00 09/29/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264405
Principal investigator 1 Merck Sharp & Dohme LLC $34,287.60 09/29/2025 Non-covered Recipient Entity
MidLantic urology
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-B15 , EV-304 No dispute reported 06/30/2026 1232927537
Principal investigator 1 Janssen Research & Development, LLC $15,734.40 09/26/2025 Non-covered Recipient Entity
Urologic Consultants
A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1175264419
Principal investigator 1 Janssen Research & Development, LLC $540.00 09/26/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175379209
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,650.00 09/24/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY
PROVONE STUDY No dispute reported 06/30/2026 1247892474
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,100.00 09/24/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY
PROVONE STUDY No dispute reported 06/30/2026 1247892477
Principal investigator 1 Merck Sharp & Dohme LLC $4,190.00 09/22/2025 Non-covered Recipient Entity
MidLantic urology
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer No dispute reported 06/30/2026 1232928023
Principal investigator 1 Ferring Pharmaceuticals AS $550.00 09/11/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242060987
Principal investigator 1 Janssen Research & Development, LLC $983.00 09/08/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175379090
Principal investigator 1 Merck Sharp & Dohme LLC $149,672.64 08/31/2025 Non-covered Recipient Entity
MidLantic urology
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232935329
Principal investigator 1 Janssen Research & Development, LLC $8,044.00 08/28/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264351
Principal investigator 1 Ferring Pharmaceuticals AS $21,772.00 08/27/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242060874
Principal investigator 1 Janssen Research & Development, LLC $1,665.05 08/25/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175378809
Principal investigator 1 Janssen Research & Development, LLC $1,918.00 08/18/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264575
Principal investigator 1 Janssen Research & Development, LLC $107.00 08/18/2025 Non-covered Recipient Entity
Urologic Consultants Of Southeastern Pennsylvania Admn
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175264591
Principal investigator 1 Janssen Research & Development, LLC $771.00 08/18/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175379111
Principal investigator 1 Janssen Research & Development, LLC $4,033.00 07/28/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175378853
Principal investigator 1 Janssen Research & Development, LLC $3,225.00 07/28/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175378961
Principal investigator 1 Janssen Research & Development, LLC $139.05 07/24/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175379096
Principal investigator 1 Janssen Research & Development, LLC $28,465.00 07/18/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264479
Principal investigator 1 Janssen Research & Development, LLC $5,721.00 07/18/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264544
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,334.82 07/14/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409106
Principal investigator 1 AstraZeneca Pharmaceuticals LP $502,463.00 07/11/2025 Non-covered Recipient Entity
MIDLANTIC UROLOGY LLC
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185543188
Principal investigator 1 Janssen Research & Development, LLC $173.00 07/07/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175379164
Principal investigator 1 Janssen Research & Development, LLC $6,192.00 07/04/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175264391
Principal investigator 1 Janssen Research & Development, LLC $4,700.00 07/04/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175264413
Principal investigator 1 Janssen Research & Development, LLC $8,285.00 07/04/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175264536
Principal investigator 1 Janssen Research & Development, LLC $2,306.00 07/04/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175378976
Principal investigator 1 Janssen Research & Development, LLC $311.00 06/30/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175379074
Principal investigator 1 Janssen Research & Development, LLC $1,758.00 06/27/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175378998
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,500.00 06/13/2025 Non-covered Recipient Entity
Midlantic Bala Cynwyd Urology Research
C3300-201 No dispute reported 06/30/2026 1227680032
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $750.00 06/13/2025 Non-covered Recipient Entity
Midlantic Bala Cynwyd Urology Research
C3300-201 No dispute reported 06/30/2026 1227680414
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,500.00 06/13/2025 Non-covered Recipient Entity
Midlantic Bala Cynwyd Urology Research
C3300-201 No dispute reported 06/30/2026 1227680787
Principal investigator 1 COLOPLAST CORP $7,895.00 06/11/2025 Non-covered Recipient Entity
Centers for Advanced Urology LLP
INTIBIA No dispute reported 06/30/2026 1226927370
Principal investigator 1 Janssen Research & Development, LLC $6,136.00 06/09/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264357
Principal investigator 1 Janssen Research & Development, LLC $20,165.00 06/09/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175378814
Principal investigator 1 Janssen Research & Development, LLC $4,002.00 06/06/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175378983
Recipient Dendreon Pharmaceuticals LLC $9,626.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891294
Principal investigator 2 Dendreon Pharmaceuticals LLC $9,626.00 06/05/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY
ProvONE No dispute reported 06/30/2026 1247892160
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,334.82 06/04/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408128
Principal investigator 1 Janssen Research & Development, LLC $1,352.75 06/02/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175378916
Principal investigator 1 MEDIVATION LLC. $240.50 06/02/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790884
Principal investigator 1 MEDIVATION LLC. $240.50 06/02/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792749
Principal investigator 1 Janssen Research & Development, LLC $449.00 05/29/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175378785
Principal investigator 1 Janssen Research & Development, LLC $18,141.00 05/19/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175378991
Principal investigator 1 Janssen Research & Development, LLC $16,494.00 05/19/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175379034
Principal investigator 1 Janssen Research & Development, LLC $16,291.00 05/19/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175379217
Principal investigator 1 Janssen Research & Development, LLC $1,918.00 05/16/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264557
Principal investigator 1 Janssen Research & Development, LLC $11,264.00 05/12/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175379158
Principal investigator 1 Janssen Research & Development, LLC $107.00 05/09/2025 Non-covered Recipient Entity
Urologic Consultants Of Southeastern Pennsylvania
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175264568
Principal investigator 1 COLOPLAST CORP $5,040.23 05/06/2025 Non-covered Recipient Entity
Centers for Advanced Urology LLP
INTIBIA No dispute reported 06/30/2026 1226927372
Principal investigator 1 MEDIVATION LLC. $240.50 05/05/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723046
Principal investigator 1 MEDIVATION LLC. $564.20 05/05/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790227
Principal investigator 1 MEDIVATION LLC. $240.50 05/05/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792903
Principal investigator 1 Janssen Research & Development, LLC $1,354.00 05/01/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175379119
Principal investigator 1 Janssen Research & Development, LLC $2,255.45 04/28/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175378768
Principal investigator 1 Janssen Research & Development, LLC $4,033.00 04/28/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175378822
Principal investigator 1 Janssen Research & Development, LLC $779.00 04/28/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175379011
Principal investigator 1 Janssen Research & Development, LLC $6,716.00 04/24/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264474
Principal investigator 1 Janssen Research & Development, LLC $11,060.00 04/11/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175379201
Principal investigator 1 Janssen Research & Development, LLC $4,955.00 04/07/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175378777
Principal investigator 1 Janssen Research & Development, LLC $4,340.00 04/07/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175379043
Principal investigator 1 Janssen Research & Development, LLC $2,416.00 04/04/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264528
Principal investigator 1 Janssen Research & Development, LLC $4,033.00 04/03/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175378931
Principal investigator 1 Janssen Research & Development, LLC $771.00 03/31/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175379132
Principal investigator 1 Janssen Research & Development, LLC $902.70 03/27/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175378924
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,334.82 03/24/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225402919
Principal investigator 1 Janssen Research & Development, LLC $10,802.00 03/17/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264520
Principal investigator 1 COLOPLAST CORP $1,359.45 03/13/2025 Non-covered Recipient Entity
Centers for Advanced Urology LLP
INTIBIA No dispute reported 06/30/2026 1226927368
Principal investigator 1 Janssen Research & Development, LLC $107.00 03/13/2025 Non-covered Recipient Entity
Urologic Consultants Of Southeastern Pennsylvania
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175264345
Principal investigator 1 Merck Sharp & Dohme LLC $19,289.40 03/12/2025 Non-covered Recipient Entity
MidLantic urology
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett No dispute reported 06/30/2026 1232924972
Principal investigator 1 Janssen Research & Development, LLC $8,290.00 03/10/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175378751
Principal investigator 1 Janssen Research & Development, LLC $12,502.00 03/10/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175379006
Principal investigator 1 Blue Earth Diagnostics $5,065.80 03/06/2025 Non-covered Recipient Entity
MidLantic Urology
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management No dispute reported 06/30/2026 1252658821
Principal investigator 1 Janssen Research & Development, LLC $1,354.00 03/03/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175378869
Principal investigator 1 MEDIVATION LLC. $240.50 03/03/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786080
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,300.00 02/26/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY
PROVONE STUDY No dispute reported 06/30/2026 1247891734
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,750.00 02/25/2025 Non-covered Recipient Entity
Midlantic Urology
BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies No dispute reported 06/30/2026 1225406422
Principal investigator 1 Janssen Research & Development, LLC $933.00 02/24/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175378801
Principal investigator 1 Janssen Research & Development, LLC $8,721.00 02/21/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264458
Principal investigator 1 Blue Earth Diagnostics $5,065.80 02/18/2025 Non-covered Recipient Entity
MidLantic Urology
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management No dispute reported 06/30/2026 1252658819
Principal investigator 1 Janssen Research & Development, LLC $23,253.00 02/17/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175378954
Principal investigator 1 Janssen Research & Development, LLC $42,268.00 02/17/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175379126
Principal investigator 1 Janssen Research & Development, LLC $35,730.00 02/17/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175379171
Principal investigator 1 Blue Earth Diagnostics $5,065.80 02/14/2025 Non-covered Recipient Entity
MidLantic Urology
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management No dispute reported 06/30/2026 1252658817
Principal investigator 1 Janssen Research & Development, LLC $1,918.00 02/13/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175264579
Principal investigator 1 Janssen Research & Development, LLC $24,914.00 02/10/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175379058
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $2,000.00 02/07/2025 Non-covered Recipient Entity
Midlantic Bala Cynwyd Urology Research
C3300-201 No dispute reported 06/30/2026 1227681228
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $10,000.00 02/07/2025 Non-covered Recipient Entity
Midlantic Bala Cynwyd Urology Research
C3300-201 No dispute reported 06/30/2026 1227681604
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $500.00 02/07/2025 Non-covered Recipient Entity
Midlantic Bala Cynwyd Urology Research
C3300-201 No dispute reported 06/30/2026 1227681957
Principal investigator 1 Blue Earth Diagnostics $5,065.80 02/06/2025 Non-covered Recipient Entity
MidLantic Urology
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management No dispute reported 06/30/2026 1252658815
Principal investigator 1 Janssen Research & Development, LLC $3,156.85 02/03/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175378891
Principal investigator 1 Janssen Research & Development, LLC $1,542.00 02/03/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175378969
Principal investigator 1 Janssen Research & Development, LLC $4,543.00 02/03/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175379026
Principal investigator 1 Blue Earth Diagnostics $5,065.80 01/31/2025 Non-covered Recipient Entity
MidLantic Urology
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management No dispute reported 06/30/2026 1252658813
Principal investigator 1 Blue Earth Diagnostics $5,065.80 01/31/2025 Non-covered Recipient Entity
MidLantic Urology
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management No dispute reported 06/30/2026 1252658885
Principal investigator 1 AstraZeneca Pharmaceuticals LP $189,159.75 01/29/2025 Non-covered Recipient Entity
MIDLANTIC UROLOGY LLC
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185543190
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $352.97 01/29/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403489
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $352.97 01/29/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406994
Principal investigator 1 Sumitomo Pharma America, Inc. $1,818.00 01/29/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY LLP DBA MIDLANTIC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176624936
Principal investigator 1 Janssen Research & Development, LLC $8,526.00 01/28/2025 Non-covered Recipient Entity
Centers For Advanced Uro Llc DBA Midlantic Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175264450
Principal investigator 1 Blue Earth Diagnostics $5,065.80 01/23/2025 Non-covered Recipient Entity
MidLantic Urology
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management No dispute reported 06/30/2026 1252658811
Principal investigator 1 Blue Earth Diagnostics $5,065.80 01/21/2025 Non-covered Recipient Entity
MidLantic Urology
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management No dispute reported 06/30/2026 1252658809
Principal investigator 1 Blue Earth Diagnostics $5,065.80 01/17/2025 Non-covered Recipient Entity
MidLantic Urology
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management No dispute reported 06/30/2026 1252658807
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403209
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403211
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,344.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404167
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,358.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404439
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405182
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405592
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405598
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405600
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405714
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406026
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $396.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406200
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406246
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,018.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406430
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,980.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406432
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406434
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406436
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406770
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.00 01/03/2025 Non-covered Recipient Entity
Regents Of The University Of California At Irvine Attn: Kenneth J Chang
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225407068